Global Tumour Immune Checkpoint Inhibitor Therapy Market Growth 2024-2030

2024

Global Tumour Immune Checkpoint Inhibitor Therapy Market Growth 2024-2030

Name: Global Tumour Immune Checkpoint Inhibitor Therapy Market Growth 2024-2030
Brand: Bonafide Research
SKU: 95001471
Price: 3450 USD
Availability: InStock
Rating: 4 (8.65 reviews)

The global tumor immune checkpoint inhibitor therapy market is projected to grow from US$ 52.24 billion in 2023 to US$ 91.28 billion in 2030, reflecting strong growth in cancer imm

Bonafide Trust
21-08-2024
Pages : 112
Figures : 81
Tables : 127
Region : Global
Category : Lifescience & Healthcare
Healthcare

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The Global Tumour Immune Checkpoint Inhibitor Therapy Market is a rapidly evolving segment within oncology therapeutics, focusing on the use of monoclonal antibodies to modulate the immune system and target cancer cells. These therapies target specific proteins such as PD-1, PD-L1, and CTLA-4, which cancer cells often exploit to evade the immune system. By inhibiting these proteins, immune checkpoint inhibitors enable the immune system to recognize and destroy cancer cells more effectively. This approach has shown significant promise in treating various cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, and more. The market is driven by the increasing incidence of cancer, advancements in biotechnological research, and strong governmental support for cancer treatments. However, challenges such as high treatment costs, limited accessibility in low-income regions, and potential immune-related adverse effects remain significant barriers. Ongoing research and development efforts are focused on expanding the indications for existing drugs, developing combination therapies, and exploring personalized medicine applications to enhance efficacy and minimize side effects. The market is expected to continue growing, with a focus on improving patient outcomes and expanding the range of treatable cancers. Immune checkpoint inhibitors are some monoclonal antibody drugs developed for the corresponding immune checkpoints.

The global Tumor Immune Checkpoint Inhibitor Therapy market size is projected to grow from US$ 52240 million in 2023 to US$ 91280 million in 2030; it is expected to grow at a CAGR of 8.3% from 2024 to 2030. Publisher' newest research report, the “Tumor Immune Checkpoint Inhibitor Therapy Industry Forecast” looks at past sales and reviews total world Tumor Immune Checkpoint Inhibitor Therapy sales in 2023, providing a comprehensive analysis by region and market sector of projected Tumor Immune Checkpoint Inhibitor Therapy sales for 2024 through 2030. With Tumor Immune Checkpoint Inhibitor Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Immune Checkpoint Inhibitor Therapy industry. This Insight Report provides a comprehensive analysis of the global Tumor Immune Checkpoint Inhibitor Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immune Checkpoint Inhibitor Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Immune Checkpoint Inhibitor Therapy market. United States market for Tumor Immune Checkpoint Inhibitor Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. China market for Tumor Immune Checkpoint Inhibitor Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Europe market for Tumor Immune Checkpoint Inhibitor Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030. Global key Tumor Immune Checkpoint Inhibitor Therapy players cover AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The Global Tumour Immune Checkpoint Inhibitor Therapy Market is segmented into various types based on the specific immune checkpoint proteins they target. PD-1/PD-L1 inhibitors are the most prominent type, targeting the programmed death-1 (PD-1) receptor and its ligand (PD-L1), which cancer cells often exploit to evade immune detection. These inhibitors, such as nivolumab and pembrolizumab, have shown significant efficacy in treating cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma. CTLA-4 inhibitors, such as ipilimumab, target the cytotoxic T lymphocyte-associated protein 4 (CTLA-4), another checkpoint protein that downregulates immune responses. These inhibitors are used in combination therapies to enhance the immune system's ability to fight cancer. The market is also witnessing the development of next-generation checkpoint inhibitors that aim to improve efficacy and reduce side effects. These advancements are driven by ongoing research and clinical trials focused on identifying new targets and optimizing existing therapies. The diversity in checkpoint inhibitor types allows for tailored treatment approaches, catering to the specific needs of different cancer types and patient populations. This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immune Checkpoint Inhibitor Therapy market by product type, application, key manufacturers and key regions and countries.

The global Tumour immunocheckpoint inhibitor therapy market is segmented into various applications, including lung cancer, breast cancer, melanoma, renal cell carcinoma, colorectal cancer, prostate cancer, bladder cancer, Hodgkin lymphoma, and other cancers. Lung cancer is one of the largest segments, given its high prevalence and the significant advancements in immune checkpoint inhibitor therapies for this type of cancer. Breast cancer and melanoma are also major segments, with numerous approved therapies showing promising results in clinical trials. Renal cell carcinoma and colorectal cancer are other key applications, benefiting from the targeted approach of immune checkpoint inhibitors. Prostate cancer and bladder cancer are emerging segments, with ongoing research and development efforts aimed at expanding the use of these therapies. Hodgkin lymphoma is another important application, with immune checkpoint inhibitors demonstrating efficacy in treating this type of cancer. The "other cancers" segment includes various less common cancers where immune checkpoint inhibitors are being explored as potential treatments. The market is driven by the increasing incidence of cancer, advancements in biotechnological research, and strong governmental support for cancer treatments. However, challenges such as high treatment costs, limited accessibility in low-income regions, and potential immune-related adverse effects remain significant barriers. Ongoing research and development efforts are focused on expanding the indications for existing drugs, developing combination therapies, and exploring personalized medicine applications to enhance efficacy and minimize side effects. The market is expected to continue growing, with a focus on improving patient outcomes and expanding the range of treatable cancers.

The Global Tumour Immune Checkpoint Inhibitor Therapy Market is segmented into several key regions, each with its own unique characteristics and growth drivers. North America is a dominant player in the market, driven by stringent healthcare regulations, a high prevalence of cancer, and significant investments in oncology research and development. The United States leads the region with a robust pipeline of immune checkpoint inhibitors and a strong focus on personalized medicine. Europe follows closely, with countries like Germany, France, and the United Kingdom leading the way due to their advanced healthcare infrastructure and supportive regulatory environment. The Asia-Pacific region, particularly China and India, is experiencing rapid growth, fueled by increasing cancer incidence, rising healthcare expenditure, and government initiatives promoting advanced cancer treatments. The region is expected to be the fastest-growing market over the forecast period. Latin America and the Middle East & Africa are also emerging markets, with increasing investments in healthcare infrastructure and the adoption of immune checkpoint inhibitors. Overall, the global tumour immune checkpoint inhibitor therapy market is poised for continued growth, driven by the need for effective cancer treatments and the ongoing advancements in immunotherapy.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Tumor Immune Checkpoint Inhibitor Therapy by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Tumor Immune Checkpoint Inhibitor Therapy by Country/Region, 2019, 2023 & 2030
2.2 Tumor Immune Checkpoint Inhibitor Therapy Segment by Type
2.2.1 PD-1/PD-L1
2.2.2 CTLA-4
2.3 Tumor Immune Checkpoint Inhibitor Therapy Sales by Type
2.3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
2.3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue and Market Share by Type (2019-2024)
2.3.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Type (2019-2024)
2.4 Tumor Immune Checkpoint Inhibitor Therapy Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Tumor Immune Checkpoint Inhibitor Therapy Sales by Application
2.5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Market Share by Application (2019-2024)
2.5.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue and Market Share by Application (2019-2024)
2.5.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Application (2019-2024)
3 Global Tumor Immune Checkpoint Inhibitor Therapy by Company
3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Breakdown Data by Company
3.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales by Company (2019-2024)
3.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Company (2019-2024)
3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue by Company (2019-2024)
3.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Company (2019-2024)
3.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Company (2019-2024)
3.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Company
3.4 Key Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Product Location Distribution
3.4.2 Players Tumor Immune Checkpoint Inhibitor Therapy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Tumor Immune Checkpoint Inhibitor Therapy by Geographic Region
4.1 World Historic Tumor Immune Checkpoint Inhibitor Therapy Market Size by Geographic Region (2019-2024)
4.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country/Region (2019-2024)
4.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales by Country/Region (2019-2024)
4.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Growth
4.4 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Growth
4.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Growth
4.6 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Growth
5 Americas
5.1 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Country
5.1.1 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024)
5.1.2 Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024)
5.2 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Type
5.3 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Region
6.1.1 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Region (2019-2024)
6.1.2 APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region (2019-2024)
6.2 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Type
6.3 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Tumor Immune Checkpoint Inhibitor Therapy by Country
7.1.1 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024)
7.1.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024)
7.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Type
7.3 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy by Country
8.1.1 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024)
8.1.2 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024)
8.2 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Type
8.3 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumor Immune Checkpoint Inhibitor Therapy
10.3 Manufacturing Process Analysis of Tumor Immune Checkpoint Inhibitor Therapy
10.4 Industry Chain Structure of Tumor Immune Checkpoint Inhibitor Therapy
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumor Immune Checkpoint Inhibitor Therapy Distributors
11.3 Tumor Immune Checkpoint Inhibitor Therapy Customer
12 World Forecast Review for Tumor Immune Checkpoint Inhibitor Therapy by Geographic Region
12.1 Global Tumor Immune Checkpoint Inhibitor Therapy Market Size Forecast by Region
12.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Forecast by Region (2025-2030)
12.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumor Immune Checkpoint Inhibitor Therapy Forecast by Type
12.7 Global Tumor Immune Checkpoint Inhibitor Therapy Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.1.3 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 Roche Holdings AG
13.3.1 Roche Holdings AG Company Information
13.3.2 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.3.3 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Roche Holdings AG Main Business Overview
13.3.5 Roche Holdings AG Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.4.3 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.5.3 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.6.3 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.7.3 Merck Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Ono Pharmaceutical
13.8.1 Ono Pharmaceutical Company Information
13.8.2 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.8.3 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Ono Pharmaceutical Main Business Overview
13.8.5 Ono Pharmaceutical Latest Developments
13.9 Regeneron
13.9.1 Regeneron Company Information
13.9.2 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.9.3 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Regeneron Main Business Overview
13.9.5 Regeneron Latest Developments
13.10 Innovent
13.10.1 Innovent Company Information
13.10.2 Innovent Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
13.10.3 Innovent Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Innovent Main Business Overview
13.10.5 Innovent Latest Developments
14 Research Findings and Conclusion

Table 1. Tumor Immune Checkpoint Inhibitor Therapy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Tumor Immune Checkpoint Inhibitor Therapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of PD-1/PD-L1
Table 4. Major Players of CTLA-4
Table 5. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)
Table 6. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
Table 7. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Type (2019-2024) & ($ million)
Table 8. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Type (2019-2024)
Table 9. Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)
Table 11. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)
Table 12. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Application (2019-2024)
Table 13. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Application (2019-2024)
Table 14. Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Company (2019-2024) & (K Units)
Table 16. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Company (2019-2024)
Table 17. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Company (2019-2024)
Table 19. Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Producing Area Distribution and Sales Area
Table 21. Players Tumor Immune Checkpoint Inhibitor Therapy Products Offered
Table 22. Tumor Immune Checkpoint Inhibitor Therapy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share Geographic Region (2019-2024)
Table 27. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country/Region (2019-2024)
Table 31. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024) & (K Units)
Table 34. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country (2019-2024)
Table 35. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country (2019-2024)
Table 37. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)
Table 38. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)
Table 39. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Region (2019-2024) & (K Units)
Table 40. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Region (2019-2024)
Table 41. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Region (2019-2024)
Table 43. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)
Table 44. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)
Table 45. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024) & (K Units)
Table 46. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country (2019-2024)
Table 47. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country (2019-2024)
Table 49. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)
Table 50. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Tumor Immune Checkpoint Inhibitor Therapy
Table 58. Key Market Challenges & Risks of Tumor Immune Checkpoint Inhibitor Therapy
Table 59. Key Industry Trends of Tumor Immune Checkpoint Inhibitor Therapy
Table 60. Tumor Immune Checkpoint Inhibitor Therapy Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Tumor Immune Checkpoint Inhibitor Therapy Distributors List
Table 63. Tumor Immune Checkpoint Inhibitor Therapy Customer List
Table 64. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. AstraZeneca Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 80. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. AstraZeneca Main Business
Table 82. AstraZeneca Latest Developments
Table 83. Bristol-Myers Squibb Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 85. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. Bristol-Myers Squibb Main Business
Table 87. Bristol-Myers Squibb Latest Developments
Table 88. Roche Holdings AG Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 89. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 90. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Roche Holdings AG Main Business
Table 92. Roche Holdings AG Latest Developments
Table 93. Novartis AG Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 95. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Novartis AG Main Business
Table 97. Novartis AG Latest Developments
Table 98. Pfizer Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 99. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 100. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Pfizer Main Business
Table 102. Pfizer Latest Developments
Table 103. Sanofi Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 104. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 105. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. Sanofi Main Business
Table 107. Sanofi Latest Developments
Table 108. Merck Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 109. Merck Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 110. Merck Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. Merck Main Business
Table 112. Merck Latest Developments
Table 113. Ono Pharmaceutical Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 114. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 115. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. Ono Pharmaceutical Main Business
Table 117. Ono Pharmaceutical Latest Developments
Table 118. Regeneron Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 119. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 120. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. Regeneron Main Business
Table 122. Regeneron Latest Developments
Table 123. Innovent Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
Table 124. Innovent Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
Table 125. Innovent Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. Innovent Main Business
Table 127. Innovent Latest Developments
List of

Figure 1. Picture of Tumor Immune Checkpoint Inhibitor Therapy
Figure 2. Tumor Immune Checkpoint Inhibitor Therapy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Tumor Immune Checkpoint Inhibitor Therapy Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of PD-1/PD-L1
Figure 10. Product Picture of CTLA-4
Figure 11. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type in 2023
Figure 12. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Type (2019-2024)
Figure 13. Tumor Immune Checkpoint Inhibitor Therapy Consumed in Hospital
Figure 14. Global Tumor Immune Checkpoint Inhibitor Therapy Market: Hospital (2019-2024) & (K Units)
Figure 15. Tumor Immune Checkpoint Inhibitor Therapy Consumed in Clinic
Figure 16. Global Tumor Immune Checkpoint Inhibitor Therapy Market: Clinic (2019-2024) & (K Units)
Figure 17. Tumor Immune Checkpoint Inhibitor Therapy Consumed in Other
Figure 18. Global Tumor Immune Checkpoint Inhibitor Therapy Market: Other (2019-2024) & (K Units)
Figure 19. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2023)
Figure 20. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Application in 2023
Figure 21. Tumor Immune Checkpoint Inhibitor Therapy Sales Market by Company in 2023 (K Units)
Figure 22. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Company in 2023
Figure 23. Tumor Immune Checkpoint Inhibitor Therapy Revenue Market by Company in 2023 ($ Million)
Figure 24. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Company in 2023
Figure 25. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Geographic Region (2019-2024)
Figure 26. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Geographic Region in 2023
Figure 27. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)
Figure 28. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 ($ Millions)
Figure 29. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)
Figure 30. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 ($ Millions)
Figure 31. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)
Figure 32. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 ($ Millions)
Figure 33. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)
Figure 34. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 ($ Millions)
Figure 35. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country in 2023
Figure 36. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country in 2023
Figure 37. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
Figure 38. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)
Figure 39. United States Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 40. Canada Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 41. Mexico Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 42. Brazil Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 43. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Region in 2023
Figure 44. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Regions in 2023
Figure 45. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
Figure 46. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)
Figure 47. China Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 48. Japan Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 49. South Korea Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 50. Southeast Asia Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 51. India Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 52. Australia Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 53. China Taiwan Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 54. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country in 2023
Figure 55. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country in 2023
Figure 56. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
Figure 57. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)
Figure 58. Germany Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 59. France Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 60. UK Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 61. Italy Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 62. Russia Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 63. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country in 2023
Figure 64. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country in 2023
Figure 65. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
Figure 66. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)
Figure 67. Egypt Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 68. South Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 69. Israel Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 70. Turkey Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 71. GCC Country Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Tumor Immune Checkpoint Inhibitor Therapy in 2023
Figure 73. Manufacturing Process Analysis of Tumor Immune Checkpoint Inhibitor Therapy
Figure 74. Industry Chain Structure of Tumor Immune Checkpoint Inhibitor Therapy
Figure 75. Channels of Distribution
Figure 76. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Forecast by Region (2025-2030)
Figure 77. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share Forecast by Region (2025-2030)
Figure 78. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share Forecast by Type (2025-2030)
Figure 79. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share Forecast by Type (2025-2030)
Figure 80. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share Forecast by Application (2025-2030)
Figure 81. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted